Skip to main content

Table 4 Comparison of score changes at scheduled visits versus baseline between groups

From: Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial

Scale

Timeframe (month after last dose)

Control (n = 20), mean ± SEM

hUC-MSC (n = 19), mean ± SEM

P valueA

ADL

1

0.658 ± 1.117

2.868 ± 1.279

0.135

3

5.975 ± 1.782

12.447 ± 2.156

0.013*

6

10.125 ± 2.250

21.053 ± 2.860

0.003*

12

12.775 ± 2.465

22.974 ± 2.936

0.009*

CFA

1

1.474 ± 1.455

4.158 ± 1.804

0.324

3

7.425 ± 2.754

17.947 ± 3.317

0.021*

6

11.925 ± 3.253

23.790 ± 3.774

0.026*

12

15.175 ± 3.785

25.737 ± 3.947

0.061

GMFM

1

4.053 ± 3.001

− 1.316 ± 3.429

0.237

3

15.700 ± 6.746

32.053 ± 5.028

0.062

6

28.900 ± 8.807

59.000 ± 8.947

0.037*

12

36.800 ± 8.802

64.526 ± 9.600

0.045*

  1. Abbreviations: ADL activities of daily living, CFA comprehensive function assessment, GMFM gross motor function measure, hUC-MSC human umbilical cord-derived mesenchymal stem cell
  2. AP value was calculated by two-way ANOVA with repeated measures
  3. *P < 0.05